In a follow-up study on 202 prospectively enrolled patients, treated with either abiraterone or enzalutamide, AR-V7 positivity was significantly associated with other adverse prognostic factors, including a Gleason score of ≥8, the presence of metastatic disease, and previous treatment with AR-directed therapies and taxanes. Here, AR is linked to metastatic neoplasm.